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ABSTRACT
Primary refractory acute leukemia (AL) has a poor prognosis, although some patients can be salvaged with
allogeneic stem cell transplantation (SCT). Induction of complete remission (CR) with conventional chemo-
therapy before SCT may improve outcome in this patient population. Between March 1991 and October 2003,
59 adults with primary refractory AL were treated with continuous-infusion etoposide (VP) 2.4 to 3.0 g/m2
followed by cyclophosphamide (Cy) 6.0-7.2 g/m2 intravenously over 3 to 4 days with the intention of
proceeding to SCT in CR1. Forty-two patients had acute myelogenous leukemia (AML), 13 patients had acute
lymphoblastic leukemia (ALL), and 4 patients had acute biphenotypic leukemia. The most frequent nonhe-
matologic toxicities were oral mucosal, gastrointestinal, and hepatic toxicities (44%, 20%, and 15% of patients,
respectively). Thirty-two (57%) of 56 evaluable patients entered CR1 with a median time to platelet and
neutrophil recovery of 22 and 26 days, respectively. CR1 rates were similar in AML (54%) and ALL/acute
biphenotypic leukemia (67%; P  .52), and analysis of baseline characteristics did not reveal any predictors of
response to VP/Cy. Twenty-nine of 32 CR1 patients subsequently underwent SCT (24 allogeneic and 5
autologous). Estimated 5-year event-free survival (EFS) and overall survival for the entire cohort are 23% and
26%, respectively. In the allogeneic SCT group, 5-year EFS was 52% for AML patients and 14% for ALL
patients (P  .04), and only male sex was predictive of a favorable outcome (P  .03). VP/Cy is able to induce
CR1 in most patients with primary refractory AL with an acceptable toxicity profile. Subsequent allogeneic
SCT can lead to long-term EFS in a significant proportion of patients.
© 2006 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Adult patients with acute leukemia (AL) refractory
o induction chemotherapy have a poor prognosis [1].
lthough several salvage regimens have been success-
ully used to induce remission in this group of pa-
ients, the duration of remission is often brief, with
ew long-term survivors [2-4]. Allogeneic stem cell
ransplantation (SCT) remains the best option for
atients with primary refractory AL [5-7]. Unfortu-
ately, the outcome for patients with AL after alloge-
eic SCT is largely dependent on disease status at the d
80ime of transplantation [8]. Patients refractory to che-
otherapy who proceed directly to SCT, especially
hose with a high leukemia cell burden and a subop-
imal performance status, are likely to do poorly [5,9].
One approach that could be applied to improve
utcomes for patients with primary refractory AL is to
rst administer salvage chemotherapy aimed at induc-
ng a complete remission (CR) and then proceed to
CT. However, a suitable salvage regimen would also
ave to have an acceptable toxicity proﬁle that would
llow for early SCT to consolidate the CR1. High-
ose cytosine arabinoside (Ara-C)–containing regi-
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VP/Cy and Transplantation for Refractory Leukemia
Bens have been shown to be useful in patients with
cute myelogenous leukemia (AML) refractory to
onventional-dose Ara-C and anthracycline therapy
10-12]. However, effective chemotherapeutic regi-
ens for AML refractory to higher doses of Ara-C are
ess well described.
High-dose etoposide (VP) and cyclophosphamide
Cy) without stem cell support was ﬁrst described by
rown et al. [13] as a salvage regimen for relapsed and
efractory AL and lymphoma. These investigators re-
orted that VP/Cy was effective in inducing a CR in
ome patients with high-dose Ara-C–resistant AML.
s a result, VP/Cy was adopted as the standard salvage
egimen for primary refractory AL at our institution in
991, with the intention of identifying patients with
ufﬁcient chemosensitivity to justify proceeding to SCT.
erein, we report on our extensive experience with this
hemotherapy regimen, focusing on the CR rate and
onhematologic toxicities associated with VP/Cy, as well
s its subsequent inﬂuence on SCT-related outcome.
ATIENTS AND METHODS
atient Characteristics
Between March 1991 and October 2003, 59 patients
ith primary refractory AL cared for at Vancouver Gen-
ral Hospital (VGH) and the British Columbia Cancer
gency were treated with continuous-infusion (CIVI)
P followed by daily intravenous (IV) Cy, as outlined
elow. Patient characteristics are detailed in Table 1.
atients were categorized as having AML, acute lym-
hoblastic leukemia (ALL), or acute biphenotypic leu-
emia (ABL) according to the World Health Organiza-
ion classiﬁcation system [14]. Patients were eligible for
P/Cy therapy if they (1) were aged 17 to 60 years, (2)
ad primary refractory disease (deﬁned as 15% leuke-
ia blast cells in the bone marrow on day 30 of standard
nduction therapy), and (3) were candidates for subse-
uent allogeneic or autologous SCT (ie, had adequate
ulmonary, cardiac, hepatic, and renal function). Pa-
ients were ineligible if they (1) had relapsed AL, (2) had
eceived more than 1 prior course of induction chemo-
herapy, or (3) were unable to give informed consent. All
esearch protocols were approved by the Clinical Re-
earch Ethics Board of VGH and the University of
ritish Columbia.
rior Treatment
Before 1997, induction therapy for AML patients
n  9) consisted of Ara-C 3 g/m2 IV on day 1
ollowed by 1.5 g/m2/d CIVI  4 days (total dose
g/m2), mitoxantrone 12 mg/m2/d IV  3 days, and
P 800 mg/m2 IV on day 5. Beginning in 1997, AML
atients (n  32) underwent induction therapy with
ra-C 1.5 g/m2 IV every 12 hours  6 days (total
ose, 18 g/m2) and daunorubicin 45 mg/m2/d IV  3 t
B&MTays. Patients with ALL (n  13) were induced with
aunorubicin 60 mg/m2/d IV  3 days, vincristine 1.4
g/m2 IV weekly  4 doses, prednisone 60 mg/m2/d
y mouth  21 days (then rapidly tapered), and (in 8
atients) l-asparaginase 10 000 units IV daily  12
oses. One patient with ALL and aberrant myeloid
ntigen expression, 1 patient with AML M1 and ab-
rrant lymphoid antigen expression, and 3 patients
ith ABL received a hybrid regimen consisting of
ra-C (total dose 18 g/m2)/daunorubicin (as described
or AML patients), as well as vincristine and pred-
isone (as described for ALL patients). In all patients,
emission status after standard induction was deter-
ined by bone marrow examination performed after
ematopoietic recovery, generally between day 21
nd day 30. A day 14 bone marrow examination
for the purpose of considering reinduction with stan-
ard chemotherapy agents) was not routinely per-
ormed.
ytogenetic Analysis
Cytogenetic studies were performed on all pa-
able 1. Patient Characteristics (n  59)
Variable Data
ge (y)
17-30 13 (22)*
31-40 13 (22)
41-50 18 (31)
51-60 15 (25)
ex
Male 39 (66)
Female 20 (34)
iagnosis
AML 42 (71)
ALL 13 (22)
ABL 4 (7)
BC count at diagnosis (109/L)
<50 48 (81)
>50 11 (19)
ytogenetic risk group†
Adverse 20 (34)
Intermediate risk 34 (58)
Favorable 4 (7)
N/A 1 (1)
arrow blast percentage‡
<40% 21 (36)
>40% 35 (59)
N/A 3 (5)
ML indicates acute myelogenous leukemia; WBC, white blood
cell; ALL, acute lymphoblastic leukemia; ABL, acute bipheno-
typic leukemia; N/A, not available.
Numbers in parentheses represent the percentage of all patients.
Adverse  AML: 5, del (5q), 7, 3q abnormality, or 5 abnor-
malities; ALL/ABL: t(9;22), t(4;11), 11q23 abnormality, or hy-
podiploid. Favorable  AML: t(8;21), inv 16, or t(15;17); ALL/
ABL: 12p abnormality, t(1;19), or hyperdiploid. Intermediate
risk  all other abnormalities not included as favorable or
adverse.
Before commencement of salvage chemotherapy.ients before induction chemotherapy by using a stan-
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4ard cultured metaphase analysis technique. Clonal
aryotypic abnormalities were detected in 42 patients
72%); only 1 patient had no analyzable metaphases.
atients were assigned to 1 of 3 Medical Research
ouncil prognostic groups as deﬁned by Grimwade
t al. [15] for AML patients and by Secker-Walker
t al. [16] for all other patients. All patients in
orphologic CR1 had cytogenetics performed if
hey had previously had a clonal abnormality doc-
mented, to conﬁrm remission status.
alvage Treatment
The vast majority of patients (n  52) received
alvage chemotherapy in a standardized fashion: VP
.4 g/m2 (maximum concentration, 0.4 g/L of normal
aline) over 34 hours CIVI commencing on day 1 and
y 2 g/m2 over 2 hours IV daily on days 3 to 5.
owever, before August 1996, 6 patients received a
igher dose of VP (3 g/m2) on day 1, and 1 additional
atient received a higher total dose of Cy (1.8 g/m2 IV
aily on days 3-6).
upportive Care
Patients were treated in a high-efﬁciency particu-
ate air–ﬁltered positive-pressure leukemia/stem cell
ransplantation facility at either VGH or the British
olumbia Cancer Agency. Uroepithelial prophylaxis
as with hyperhydration 3 L/m2/d beginning at the
nd of the VP infusion and continuing until 48 hours
fter completion of the ﬁnal Cy dose. IV antibiotics,
cyclovir, and irradiated cytomegalovirus-negative
lood products were used as indicated. Patients not
aking IV antibiotics at the commencement of salvage
herapy were placed on prophylactic ciproﬂoxacin 500
g orally every 12 hours. Beginning in June 1992,
outine antifungal prophylaxis was used with ﬂucon-
zole 200 to 400 mg by mouth or IV daily. This was
odiﬁed to amphotericin B 10 mg/m2/d IV in Decem-
er 1994.
tem Cell Transplantation
All patients who entered a CR1 with VP/Cy
alvage chemotherapy were offered high-dose che-
otherapy/radiotherapy and, preferentially, alloge-
eic SCT. Conditioning for allogeneic SCT (n 
9) was with Cy and total body irradiation in 15
atients, busulfan and Cy in 11 patients, and other
egimens in 3 patients. The allogeneic stem cell
ource was a sibling donor in 16 patients (mis-
atched in 3 patients) and a volunteer unrelated
onor in 13 patients (mismatched in 2 patients).
onor bone marrow was used in 22 patients, blood
tem cells were used in 6 patients, and both prod-
cts were used in 1 patient. Graft-versus-host dis-
ase (GVHD) prophylaxis was with CIVI cyclospor-
ne and short-course methotrexate in 26 patients, d
82nd 1 patient also received interleukin 2 receptor
ntibody (BT 563; Biotest, Dreieich, Germany). An
dditional 2 patients received cyclosporine and T
ell–depleted donor bone marrow. Five patients
ho entered CR1 with VP/Cy and either were be-
ond the institutional age limit for allogeneic SCT
n  4) or did not have a suitable donor (n  1)
nderwent autologous SCT according to a separate re-
earch protocol. Conditioning before autologous SCT
as busulfan based in all cases. The autologous stem cell
roduct was unpurged peripheral blood (n 2) or bone
arrow (n  1), 4-hydroperoxycyclophosphami-
e(HC)–purged bone marrow (n  1), or interleukin
–purged peripheral blood (n  1). Prophylactic anti-
iotics were not used during SCT, but antifungal,
ntiviral, and uroepithelial prophylaxis was adminis-
ered as described previously for VP/Cy salvage. Ad-
itionally, patients who received high-dose busulfan
outinely received phenytoin as seizure prophylaxis.
oxicities
For VP/Cy, white blood cell recovery was de-
ned as the ﬁrst of 3 consecutive days with an
bsolute neutrophil count (ANC) 0.5  109/L,
nd platelet recovery was deﬁned as the ﬁrst of 3
onsecutive days with a platelet count 20  109/L,
ndependent of transfusion. The date of the last red
lood cell transfusion was used as a surrogate marker of
ed blood cell recovery. Nonhematologic toxicity attrib-
ted to VP/Cy and that after SCT were both graded
ccording to the regimen-related toxicity (RRT) cri-
eria described for high-dose therapy regimens by
earman et al. [17]. In brief, grade 1 toxicity was mild
nd did not require medical intervention, grade 2
oxicity was moderate and necessitated medical treat-
ent, grade 3 toxicity was considered life threatening,
nd grade 4 toxicity was fatal.
esponse Criteria
Patients underwent bone marrow examination at
he time of hematologic recovery if there was reap-
earance of peripheral blood blasts or if there was no
ign of count recovery at day 30. Patients were deﬁned
s being in CR1 if their bone marrow aspirate con-
ained 5% leukemic blasts with evidence of normal
aturation of other marrow elements together with
ecovery of peripheral blood counts (ANC 1.0 
09/L, platelets 100  109/L, and blood product
ndependence). As noted previously, cytogenetic anal-
sis was used to determine remission status in patients
ith a known karyotypic marker.
efinition of End Points
Patients who died on or before day 21 of VP/Cy
ere classiﬁed as induction deaths. Patients beyond
ay 21 who were not in remission at the time of
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VP/Cy and Transplantation for Refractory Leukemia
Beath were classiﬁed as having refractory AL. Over-
ll survival (OS) was calculated for all patients from
he ﬁrst day of salvage chemotherapy (day 1).
vent-free survival (EFS) was calculated for the
ntire cohort; patients who did not enter remission
ere censored at day 1. For patients who entered
R1 with VP/Cy, the actuarial risk of relapse was
lso calculated from day 1 of salvage by censoring at
eath in CR1.
tatistical Methods
OS, EFS, and actuarial risk of relapse, acute
VHD, chronic GVHD, and transplant-related mor-
ality (TRM) were determined by the Kaplan-Meier
ethod [18]. Prognostic characteristics for response
o VP/Cy salvage were assessed by using a univariate
ox regression analysis [19]. Factors analyzed in-
luded age (40 versus 40 years), sex, type of leu-
emia (AML versus other), white blood cell count at
iagnosis (50 versus 50  109/L), Medical Re-
earch Council cytogenetic risk group, and bone mar-
ow blast percentage before salvage chemotherapy
40% versus 40%). These factors were similarly
nalyzed with respect to outcome for patients who
ubsequently underwent SCT.
ESULTS
esponse to Salvage Therapy
Thirty-two (57%) of 56 evaluable patients at-
ained a CR after VP/Cy salvage therapy. Three pa-
ients died during induction, before day 21 (1 AML,
ALL, and 1 ABL), and were therefore not evaluable
or response to VP/Cy. The CR rate with salvage
able 2. Response to Etoposide and Cyclophosphamide in Evaluable
atients (n  56), with a Median Follow-up of 11 Months
Variable All Patients
AML
(n  41)
ALL
(n  12)
ABL
(n  3)
omplete remission 32 (57)* 22 (54) 8 (67) 2 (67)
SCT 29 20 7 2
TRM 7 4 3 —
Leukemia death 9 6 3 —
Surviving 16 12 2 2
efractory leukemia 24 (43)* 19 (46) 4 (33) 1 (33)
SCT 5 5 — —
TRM† 2 2 — —
Leukemia death 20 16 3 1
Surviving 2 1 1 —
ML indicates acute myelogenous leukemia; ALL, acute lym-
phoblastic leukemia; ABL, acute biphenotypic leukemia;
SCT, stem cell transplantation; TRM, transplantation-re-
lated mortality.
Numbers in parentheses represent the percentage of evaluable
patients.pAfter salvage allogeneic SCT.
B&MTherapy was similar for all types of AL (P  .52), as
hown in Table 2.
oxicities of VP/Cy
All patients who received VP/Cy experienced
rofound pancytopenia. Of the 3 patients who died
efore day 21, 1 patient died from pulmonary hem-
rrhage (day 16), and 2 patients died from infec-
ions on day 19 (stenotrophomonas bacteremia) and
ay 20 (idiopathic pneumonitis). The patients who
id not achieve CR (n  24) were not evaluable for
ematologic recovery. For the remaining 32 pa-
ients, the median time to platelets 20  109/L
nd ANC 0.5  109/L was 22 days (range, 8-73
ays) and 26 days (range, 18-37 days), respectively.
he median time to last red blood cell transfusion
as 21 days (range, 0-52 days). The most common
onhematologic toxicities were oral mucosal (44%
f patients), gastrointestinal (20% of patients), and
epatic toxicity (15% of patients). Grade 2 oral
ucosal toxicity was severe enough to require CIVI
arcotics for pain control. Grade 2 gastrointestinal
oxicity was present when patients had more than 2
of culture-negative diarrhea per day, ileus or
leeding without hemodynamic instability, or a de-
rease in hemoglobin. Grade 2 hepatic toxicity was
eﬁned as 1 or more of the following: total bilirubin
102 mmol/L, aspartate aminotransferase 5 times
aseline, or hepatic dysfunction associated with a
5% weight gain. However, with the exception of
he 1 death from pulmonary hemorrhage, no grade
or 4 toxicities were observed.
tem Cell Transplantation
Of the 32 patients who entered CR1 with VP/
y, only 3 patients did not proceed to SCT. One
atient refused further therapy and remains alive
ith ongoing evidence of a preexisting myelodys-
lastic syndrome, 1 patient died of invasive aspergil-
osis, and a suitable donor could not be identiﬁed
or 1 patient. Five patients (4 AML patients and 1
BL patient) proceeded to autologous SCT in CR1,
of whom relapsed after SCT. Twenty-four pa-
ients underwent allogeneic SCT in CR1 (16 pa-
ients with AML, 7 patients with ALL, and 1 patient
ith ABL), as did 5 patients with AML refractory to
P/Cy. The median time from commencement of
P/Cy salvage to SCT was 71 days (range, 49-165
ays) and was not predictive of outcome. Seven of
7 patients who underwent SCT within 70 days and
of 17 patients who underwent SCT more than 70
ays after starting VP/Cy remain in CR1. The EFS
or the 29 patients who underwent allogeneic SCT
as 45% (Figure 1). Thirteen patients survive in
R1 (7 of 16 patients after sibling SCT and 6 of 13
atients after unrelated donor SCT), 7 patients re-
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4apsed (actuarial risk, 33%), and 9 patients died of
RM (actuarial risk, 26%). Six (40%) of the 15
llogeneic SCT patients conditioned with Cy/total
ody irradiation and 7 (64%) of the 11 patients
onditioned with busulfan and Cy remain alive in
R1 (P  .73).
omplications of SCT
The most frequent grade 2 to 4 RRTs seen with
llogeneic SCT were oral mucosal (79%), hepatic
38%), cardiac (14%), and renal (10%). Additionally, 2
atients developed grade 2 gastrointestinal toxicity,
nd 1 patient had grade 2 pulmonary toxicity. No
rade 3 toxicities were observed, and only 2 grade 4
oxicities were seen (both hepatic veno-occlusive dis-
ase). The cumulative risk of acute and chronic
VHD after allogeneic SCT in the study cohort was
6% and 79%, respectively. In the autologous SCT
atients, 3 patients experienced grade 2 oral mucosal
oxicity, 1 of whom also developed grade 2 hepatic
igure 1. Event-free survival for 29 patients who underwent allogen
or primary refractory leukemia (median follow-up, 11 months).
igure 2. Event-free survival for 16 patients with primary refrac
ransplantation in ﬁrst complete remission after etoposide and cyclophosp
84oxicity. No other signiﬁcant nonhematologic toxici-
ies were observed after autologous SCT.
CT Outcome in AML
Of the 16 patients with AML who proceeded to
llogeneic SCT in CR1, 11 (69%) remain alive and
ell (Figure 2). One patient relapsed 7 months after
CT, and 4 patients died of complications, includ-
ng 2 patients from GVHD, 1 patient from regi-
en-related organ toxicity, and 1 patient from an
nvasive fungal infection. Of the 5 patients who
nderwent allogeneic SCT for primary refractory
ML, 2 patients died of TRM, and 3 patients re-
apsed. However, 1 of the patients who relapsed was
ubsequently salvaged with further chemotherapy
nd a donor leukocyte infusion and remains in a
R2 of more than 2 years’ duration. All 4 patients
ith AML in CR1 who underwent autologous SCT
elapsed and died of disease.
cell transplantation after etoposide and cyclophosphamide salvage
cute myelogenous leukemia who underwent allogeneic stem celleic stemtory a
hamide salvage therapy (median follow-up, 11 months).
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BCT Outcome in ALL and ABL
Although patients with ALL had a high CR1
ate after VP/Cy salvage therapy, EFS after subse-
uent allogeneic SCT (n  7) was only 14%, which
s signiﬁcantly inferior to the EFS observed in AML
atients (52%; P  .04), even when patients who
nderwent SCT when refractory to VP/Cy were
ncluded (Figure 3). Only 1 ALL patient remains
live in CR1 after SCT, 3 patients relapsed, and 3
atients died of TRM (1 each from GVHD, RRT,
nd invasive fungal infection). One of the ALL
atients relapsed in the central nervous system 8
onths after allogeneic SCT but remains alive in
R2 more than 2 years after receiving intrathecal
hemotherapy. Both patients with ABL who at-
ained CR1 after salvage therapy are alive and well
fter SCT, including 1 patient who is now 14 years
fter 4-HC–purged autologous SCT.
verall Outcome
Eighteen patients remain alive: 4 patients with
ersistent or relapsed AL (2 of whom entered CR2,
igure 3. Event-free survival for patients who underwent allogene
ccording to type of leukemia (median follow-up, 11 months).
igure 4. Event-free survival for 59 patients with primary refracto
herapy (median follow-up, 11 months).
B&MTs noted previously) and 14 patients in a continuous
R1. The OS and EFS for the entire cohort are
6% and 23%, respectively, and the median fol-
ow-up of survivors is 11 months (range, 0.6-143
onths). EFS for all study patients is shown in
igure 4.
redictors of Outcome
None of the baseline characteristics analyzed was
ound to be predictive of achieving a CR1 with VP/Cy
alvage therapy (Table 3). Eleven (58%) of 19 evalu-
ble patients with an adverse karyotype attained a CR1
ith VP/Cy, compared with 20 (56%) of 36 patients
ith a favorable or intermediate-risk karyotype. A
ubset analysis for predictors of outcome after alloge-
eic SCT (Table 3) revealed that male sex was asso-
iated with a favorable EFS (P  .03). Once again,
one marrow karyotype did not inﬂuence EFS in the
llogeneic SCT subgroup (Figure 5). Five (26%) of
he adverse-karyotype patients are alive in CR1,
patients relapsed, and 2 patients died of TRM. Eight
22%) of the favorable/intermediate-risk karyotype
cell transplantation after etoposide and cyclophosphamide salvage
te leukemia treated with etoposide and cyclophosphamide salvageic stemry acu485
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4atients are in a continuous CR1, 6 patients relapsed,
nd 4 patients died of TRM.
ISCUSSION
The prognosis for patients with AL that is refrac-
ory to standard induction chemotherapy is poor [1].
he vast majority of patients do not achieve remission
ith salvage chemotherapy, and for those who do,
emission is usually brief. Previous studies have sug-
ested that for patients with relapsed or refractory
igure 5. Event-free survival for patients with primary refractory ac
able 3. Results of Univariate Analysis for Complete Remission to
toposide and Cyclophosphamide (n  56) and Event-Free Survival
fter Stem Cell Transplantation (n  34)
Variable CR P Value EFS P Value
ge (y)
<40 0.50 0.43
>40 0.63 .32 0.35 .48
ex
Male 0.59 0.48
Female 0.53 .63 0.18 .03
eukemia type
AML 0.54 0.40
ALL/ABL 0.67 .39 0.33 .49
BC count (109/L)
<50 0.60 0.38
>50 0.38 .66 0.40 .83
ytogenetic risk group
Adverse 0.58 0.31
Intermediate risk 0.56 0.40
Favorable 0.50 .87 1.00 .79
N/A 1.00 1.00
arrow blast percentage*
<40% 0.57 0.44
>40% 0.63 .53 0.35 .57
R indicates complete remission rate; EFS, event-free survival rate;
AML, acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; ABL, acute biphenotypic leukemia; N/A, not available
(failed); WBC, white blood cell.
Before commencement of etoposide and cyclophosphamide sal-
vage therapy.ccording to cytogenetic risk group (median follow-up, 11 months).
86ML after conventional-dose Ara-C, remission rates
f 40% to 80% can be achieved with higher doses of
ra-C (12-54 g/m2) [10,20-22]. However, intensiﬁed
ra-C dosing in combination with daunorubicin or
itoxantrone has been used as standard induction
hemotherapy at our institution for the past 2 decades
n patients up to age 60 years with newly diagnosed
ML. Salvage chemotherapy in this setting is partic-
larly challenging and has not been well studied.
In patients with primary refractory ALL, the CR
ate with traditional salvage regimens is considerably
ower than what has been described with high-dose
ra-C in AML [10,23]. High-dose Ara-C has also
een used in refractory ALL and, when administered
s a single agent, has been associated with a 20% CR
ate [24]. The CR rate for high-dose Ara-C in com-
ination with idarubicin or mitoxantrone in resistant
LL has been reported to be 30% [25-27].
Although it should be noted that day 14 bone
arrow examinations were not performed and rein-
uction with standard chemotherapy agents was not
ttempted, the overall CR rate observed in our cohort of
rimary refractory AL patients was a gratifying 57%.
his included 54% of patients with AML resistant to 9
o 18 g/m2 of Ara-C and 67% of refractory ALL and
BL patients. Furthermore, none of the factors ana-
yzed, including the cytogenetic risk group, affected the
R rate. This conﬁrms the suitability of VP/Cy as a
alvage regimen for all primary refractory AL patients.
Although allogeneic SCT can be used to treat
atients with primary refractory AL, numerous studies
ave shown unfavorable results for patients who pro-
eed directly to SCT [9,12]; the leukemia cell burden
orrelates with SCT outcome [5,28]. Our institutional
esults with allogeneic SCT in primary refractory AL
n the 1980s were poor, with no long-term survivors
esulting from this treatment approach. The initial
ntent of this study was to develop a salvage regimen
hat could induce a CR1 in patients with AML refrac-
emia treated with etoposide and cyclophosphamide salvage therapyute leuk
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Bory to aggressive Ara-C treatment doses, thereby
llowing for a more successful outcome with subse-
uent SCT. High-dose VP and Cy salvage therapy
without stem cell support) was shown to be effective
n some AML patients with high-dose Ara-C–resistant
isease and in patients with refractory ALL and lym-
homa [13]. It was decided to use this VP/Cy regimen,
lthough the duration of CR in this patient cohort was
xpected to be short [13]. Consequently, the overall
anagement plan at our center included proceeding
romptly to SCT once a CR1 was achieved.
In single-agent phase I studies, the dose-limiting
onhematologic toxicity of VP has been shown to be
ucositis [29]. Severe mucosal toxicity may result in
n increased risk of bacteremia and invasive fungal
nfection during the period of myelosuppression. In
ur VP/Cy patient cohort, mucosal toxicity was ac-
eptable; only 1 patient experienced grade 3 RRT
pulmonary hemorrhage). The median time to hema-
ologic recovery was not unreasonable, and the inci-
ence of infectious deaths was only 5%. In patients
ho entered CR1, VP/Cy therapy did not preclude
imely SCT, and TRM with SCT (26%) was not
xcessive, particularly when more than half of the
ecipients underwent SCT with a mismatched-related
r an unrelated donor. The TRM observed in our
CT patients contrasts with the results reported with
CT in primary refractory AL, for which TRM has
een reported to be 40% to 50% [5,6,30]. In primary
efractory AL patients, the persistence of leukemia
ay not allow adequate time to recover from prior
herapy before proceeding to high-dose conditioning,
nd subsequent lysis of leukemia cells can further
ontribute to organ toxicity.
It is worth noting that the use of allogeneic blood
ells (rather than bone marrow) as a stem cell source
ould further improve on our reported results by re-
ucing TRM [31] and may reduce relapse by promot-
ng the development of chronic GVHD [32]. Re-
uced-intensity conditioning SCT has also been
roposed as a treatment strategy that is associated
ith a lower TRM than that seen with more conven-
ional allogeneic SCT [33]. However, this approach
as its limitations in diseases that have a rapid growth
ate, such as might be expected with refractory AL.
For the patients in our study cohort who under-
ent allogeneic SCT in CR1, long-term EFS was
easonable for patients with AML (69%) and patients
ith ABL (50%), with only 1 relapse observed to date.
owever, it should be emphasized that the median
ollow-up after SCT for these patients is 1 year, and
t is still possible that late relapse or TRM could occur
n a proportion of patients. The outcome for patients
ith ALL in CR1 was inferior to that observed in
ML/ABL (EFS of 14%) because of a higher risk of
oth TRM and relapse after SCT. This result is sim-
lar to what has previously been reported for adult W
B&MTLL patients undergoing allogeneic SCT [11,34,35],
lthough better outcomes have been observed in high-
isk pediatric ALL cohorts [36,37]. It may be that novel
onditioning regimens will be required to improve re-
ults in adult ALL because the graft-versus-leukemia
ffect seems to be less potent than in AML [38]. Al-
hough the number of such patients was small, autolo-
ous SCT after VP/Cy salvage was of limited value in
ur experience, as was proceeding to allogeneic SCT
ith patients who do not enter CR1 with VP/Cy.
Not unexpectedly, survival after treatment with
P/Cy salvage was dependent on further treatment
ith allogeneic SCT. However, EFS for the entire
P/Cy patient cohort seems to be superior to what
as previously been reported for salvage chemo-
herapy regimens in AML [10,12] and compares
avorably to registry results for allogeneic SCT in
rimary refractory AML [5,30]. Achieving a CR1
ith VP/Cy salvage may have reduced the leukemia
urden before SCT and almost certainly identiﬁed a
roup of patients who were more likely to beneﬁt
rom SCT. A recent update of SCT results in pri-
ary refractory AML from the City of Hope re-
orted a 31% EFS, although 40% of the patient
ohort had never received high-dose Ara-C before
roceeding to SCT [6]. The outcome in this study
as far inferior for individuals with an adverse
aryotype and for patients who underwent unre-
ated donor SCT—2 factors that did not inﬂuence
utcome in our study. The only predictor of SCT
utcome after VP/Cy was male sex, which may have
elated to a younger median age and a higher pro-
ortion of matched sibling SCTs in the male sub-
roup.
In conclusion, high-dose VP and Cy (without
tem cell support) is an effective salvage regimen for
rimary refractory AL and has an acceptable toxic-
ty proﬁle. It seems to be a useful strategy for
electing patients who are more likely to beneﬁt
rom allogeneic SCT, and patients who attain a CR
hould proceed to an early related or unrelated
onor SCT. Although CR rates with this salvage
egimen are acceptable in ALL, the outcome with
ubsequent allogeneic SCT remains unsatisfactory,
nd novel therapeutic strategies will be required if
hese results are to be improved.
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